Brown and his colleagues generated an off-the-shelf, steroid-resistant, IL13Rα2-targeted CAR-T and found it was safety and induced transient tumor reduction and/or tumor necrosis in patients with glioblastoma (57). Here, IL13RA2 is linked to neoplasm.